EcoR1 Capital’s Pacira BioSciences PCRX Stock Holding History

EcoR1 Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-457,471	Closed	-$10.9M	–	38
2025 Q2	$10.9M	Buy	+457,471	New	+$11.5M	0.65%	26

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EcoR1 Capital's PCRX Position: Q3 2025 in Review

EcoR1 Capital sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 457,471 shares — an estimated $10.9M sold.

EcoR1 Capital first reported a position in PCRX in Q2 2025 and held it in 1 quarter. The position peaked at $10.9M in Q2 2025. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

EcoR1 Capital reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
EcoR1 Capital sold 457,471 Pacira BioSciences shares in Q3 2025, an estimated $10.9M.
EcoR1 Capital first reported a position in Pacira BioSciences in Q2 2025 and held it in 1 quarter.
EcoR1 Capital's Pacira BioSciences position peaked at $10.9M in Q2 2025.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on EcoR1 Capital's 13F filing for Q3 2025, filed 14 Nov 2025.